A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
A phase 1/2 trial of DCC-3009 in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, now recruiting.
Overview
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) is a phase 1/2 interventional study registered as NCT06630234 by Deciphera Pharmaceuticals, LLC, with 120 participants planned, started 2024-12-10 and due to reach its primary completion in 2028-05. Interventions recorded: DCC-3009.
Similar pages
not linked directly; found by shared links- TrialA Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Shares Deciphera Pharmaceuticals (Ono), Gastrointestinal stromal tumour (GIST) and the tag pipeline.
- TrialINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
- TreatmentNB003
Shares Gastrointestinal stromal tumour (GIST) and the tag pipeline.
- TrialA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.